Intas Pharmaceuticals has launched Oral Azacitidine in India under the brand name of Azadine-O. The product is approved for use in maintenance therapy for adult patients with Acute Myeloid Leukaemia. It is the first drug that will improve survival by almost ten months and bridge a long-pending unmet need in cancer therapy, a company statement notified.
It is the first Indian pharmaceutical company to do so, the statement claimed.
It also said that in 2014, Intas triggered a paradigm change in the treatment of MDS – myelodysplastic syndrome with the launch of Azadine (injectable Azacitidine).
Speaking in this regard, India’s leading haematologist Professor (Dr) M B Agarwal said, “Oral Azacitidine will prove to be extremely useful for AML patients. There was a dire need for this drug. It shall significantly improve survival and quality of life of patients.”